Boryung (003850) has signed a seven-year supply agreement worth $277,144,985, or about ₩383.7 billion, with China's Yifan Pharmaceutical for Taxotere, a cancer drug whose active ingredient is docetaxel. The contract is Boryung's largest supply agreement and requires annual minimum purchases, with compensation provisions if volumes fall below agreed levels. Revenue will be recognized as products are supplied. The deal is Boryung's first major supply contract since it completed the acquisition of Taxotere's global business from Sanofi on May 29. China is the largest revenue market among the 19 countries and regions covered by that acquisition. Boryung expects Taxotere to generate at least ₩90 billion, or about $66.2 million, in annual revenue from 2027. The company plans to shift production to its Yesan campus through technology transfers and country-by-country regulatory approvals, while pursuing active pharmaceutical ingredient internalization, formulation improvements, additional original-drug acquisitions and expansion of its cytotoxic cancer drug CDMO business. Boryung has set a target of at least ₩300 billion, or about $220.7 million, in global revenue by 2030.